Why the study?
Recommendations for platelet function analyser screening vary according to user experience as the PFA-100 approaches 50 years of age.
The PFA-100 and PFA-200 are prevalent platelet function screening instruments with high sensitivity for von Willebrand disease and aspirin therapy, though clinical utility varies by user experience.
Answers are grounded in this paper and cite their sources.
May miss platelet defects on screening; leaves open need for prospective validation before routine use.
The platelet function analyser (PFA) is a prevalent platelet function screening instrument, and comes in two models-the original PFA-100 and the contemporary PFA-200. The instruments have 'identical' output, being a 'closure time' (CT). Moreover, normal reference ranges provided by the manufacturer, for the specific test cartridges, are the same for both models. There are three different types of test cartridge: collagen/epinephrine (C/Epi), collagen/adenosine diphosphate (C/ADP), and "Innovance PFA P2Y" (only available in certain geographical locations). The PFA-100 was released in the mid 1990s, and so is approaching 50 years of age. The PFA-200, released in some locations in the mid 2010s, is destined to eventually replace the PFA-100, but is not yet available in the USA. The test system is highly sensitive to von Willebrand disease (VWD; C/Epi and C/ADP) and to aspirin therapy (C/Epi only), but only has moderate sensitivity to defects in platelet function and/or deficiencies in platelet number. Accordingly, recommendations for use for screening platelet function vary according to user experience. Some workers have alternatively used the PFA to assess thrombosis risk or pre-operative bleeding risk. In this review, we provide an overview of the history of PFA, and summarise its current clinical utility.
No takes yet. Share an insight, caveat, or question.
Favaloro et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: